Apollon Formularies plc

AQSE Growth Market -
Apollon Formularies Plc is a medical cannabis company based in the Commonwealth of Jamaica. It holds a suite of licences that allow for fully regulated seed through to human trial & drug discovery designed for patient treatment applications. Apollon Jamaica (Apollon UK’s subsidiary) is Cannabis Licensing Authority approved to produce large scale full spectrum cannabis oils that it can sell to patients via its regulated dispensary located at its state-of-the-art large scale processing laboratory, Negril, Jamaica.

Apollon Jamaica is fitted to produce high volume, high quality, full spectrum medical cannabis oil with both high and low THC content and holds a Research & Development full spectrum license (inclusive of THC). This allows the company to undertake physician-led, medically supervised treatments for the purposes of drug discovery, all overseen and approved by the Jamaican Ministry of Health.

The company’s aim is to ensure that Apollon is the recognised global brand for quality, consistency and efficacy.
Symbol Ccy Code Bid Ask Mid Previous Close Volume Last Traded
APOL GBX 2.6 2.8 2.7 2.7 14827 08.10.21

MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.

Key Information

  
Market Cap: £20,206,170
ISIN:IM00BJ0LRD77
Par:0
Inst Type:Ordinaries
Symbol:APOL
MIFID Status:MTF
Tradable securities in issue:748,376,677
Sector:Pharmaceuticals & Biotechnology
% price change since listing:-61.43%
% daily price change:0.00%

Latest Trades

Date & Time Volume Price
08.10.21  |  15:30:59148272.6
04.10.21  |  13:46:17500002.6
30.09.21  |  09:15:332422.7
20.09.21  |  13:43:03422962.7
17.09.21  |  12:24:02120002.7
15.09.21  |  15:49:3784272.7
15.09.21  |  08:27:53367412.7
13.09.21  |  12:58:4250002.9
13.09.21  |  12:55:49300002
13.09.21  |  12:10:0316542.9

Latest Announcements

Date & Time Title
30.09.21  |  16:08:00Apollon Formularies - Interim Results
15.09.21  |  07:00:00Apollon Formularies - Substantial Increase to Production Capacity
30.07.21  |  08:00:00Apollon Formularies - Extension of Right to Purchase on CBev Ventures
21.07.21  |  07:00:00Apollon Formularies - Senior Appointment Announcement
19.07.21  |  07:00:00Apollon Formularies - Apollon Formulations Kill Prostate Cancer Cells
15.07.21  |  07:00:00Apollon Formularies - Appointment of Medical Director
01.07.21  |  07:00:00Apollon Formularies - Extension of Right to Purchase on Doc’s Place
30.06.21  |  16:46:00Apollon Formularies - Annual Report for Year Ended 31 December 2020
28.06.21  |  07:00:00Apollon Formularies - Apollon Formulations Kill TNBC Cells
14.06.21  |  07:00:00Apollon Formularies - Apollon Secures Cancer Treatment Facility

Address

Business Address

Apollon Formularies plc, 42 One Love Drive, West End, Negril, Westmoreland, Jamaica.

Email: barnhillmd@sprynet.com

Phone: +44 (0)20 7440 0640

Registered Address

34 North Quay, Douglas, Douglas, Isle of Man, IM1 4LB, United Kingdom.

Contacts

Corporate Adviser

Peterhouse Capital Ltd, 3rd Floor, 80 Cheapside, London, United Kingdom.

Email: info@pcorpfin.com

Phone: +44 (0)20 7469 0930

Registrar

Share Registrars Ltd, The Courtyard, 17 West Street, Farnham, Surrey, GU9 7DR, United Kingdom.

Email: enquiries@shareregistrars.uk.com

Phone: 01252 821390

Research


I'm sorry there is no research for this company.